Get the Stockscreener App
0.369
2.61%
-0.0099
Organovo Holdings Inc stock is traded at $0.369, with a volume of 138.15K.
It is down -2.61% in the last 24 hours and down -3.91% over the past month.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
See More
Previous Close:
$0.3789
Open:
$0.379
24h Volume:
138.15K
Relative Volume:
0.69
Market Cap:
$5.67M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-0.17
EPS:
-2.17
Net Cash Flow:
$-16.92M
1W Performance:
-4.40%
1M Performance:
-3.91%
6M Performance:
-35.83%
1Y Performance:
-63.10%
1-Day Range:
$0.361
$0.385
1-Week Range:
$0.36
$0.3996
52-Week Range:
$0.3154
$1.74
Organovo Holdings Inc Stock (ONVO) Company Profile
Name
Organovo Holdings Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA
Compare ONVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONVO
Organovo Holdings Inc
|
0.369 | 5.67M | 0 | -19.09M | -16.92M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Organovo Holdings Inc Stock (ONVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Organovo Holdings Inc Stock (ONVO) Latest News
Organovo Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Organovo: Fiscal Q3 Earnings Snapshot - Thehour.com
Organovo: Fiscal Q3 Earnings Snapshot -February 19, 2025 at 09:18 am EST - Marketscreener.com
ORGANOVO HOLDINGS, INC. SEC 10-Q Report - TradingView
Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Organovo Holdings Delays Quarterly Report Filing - TipRanks
3D Bioprinting and Bioink Market is set to Fly Massive Growth in Years to Come: Organovo, Cellink, RegenHU - openPR
Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com - Defense World
3D Bioprinting Market Research Report USD 6.4 Billion - openPR
Organovo (ONVO) Projected to Post Earnings on Thursday - Defense World
Organ On Chip Market Growing Rapidly: Emulate Inc., Mimetas B.V., Insphero, Organovo Holdings - openPR
Next Generation Bioprinting Market Top Companies StudyEOS - openPR
3D Bioprinting Market: Future Scope, Growth Potential, - openPR
Organovo faces potential Nasdaq delisting - MSN
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com - Defense World
3D Bioprinting Technology Market to Witness Stunning Growth | - openPR
Organovo faces potential Nasdaq delisting By Investing.com - Investing.com UK
3D Bioprinting in Medical Market Worth $4.9 billion by 2032 | - openPR
Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Organovo names new CFO amid clinical advancements By Investing.com - Investing.com Nigeria
Organovo Appoints Norman Staskey as Chief Financial Officer - citybiz
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Manila Times
Organovo names new CFO amid clinical advancements - Investing.com
Organovo Appoints M&A Veteran CFO as FXR314 Drug Shows Promising Phase 2 Results - StockTitan
Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com - Defense World
Organovo appoints new president and CFO amid strategic plans By Investing.com - Investing.com Nigeria
Organovo appoints new president and CFO amid strategic plans - Investing.com India
Organovo Holdings Appoints Norman Staskey as New CFO - TipRanks
Analyzing Sorrento Therapeutics (OTCMKTS:SRNEQ) and Organovo (NASDAQ:ONVO) - Defense World
Top 10 4D Printing Companies | Provides Best TechMarket.us Scoop - Market.us Scoop - Market News
Healthcare 4D Printing Market Top Companies Study3D Systems - openPR
3D Print Organ Market 2024 to Witness Huge Growth by 2032 Prominent Players are Organovo Holdings, EnvisionTEC - openPR
3D Bioprinting for Tissue and Organ Regeneration Market Top - openPR
3D Bioprinting Equipment Sales Market Overview, Future Trends - openPR
3D-Printed Organs Market is experiencing new opportunities & competitive edge highlighted by Top Market Key Players (Organovo Holdings Inc., Modern Meadow, Poietis, REGEMAT 3D S.L., Cellbricks, Nano3D Biosciences, Inc.) | Forecast to 2030 - Industry Today
Empowering Growth: Bioprinting Services Market 2024 - openPR
3D Bioprinting Market is Forecast to Achieve USD 2.0 Billion - openPR
ONVO (Organovo Holdings) Enterprise Value : $5.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Organovo expands equity incentive plan following stockholder approval By Investing.com - Investing.com Nigeria
Organovo expands equity incentive plan following stockholder approval - Investing.com
Organovo Holdings Gains Approval for Key Strategic Moves - TipRanks
Industrial 3D Printing Market Size Analysis and Top Companies - Precedence Research
ONVOOrganovo Holdings Inc. Latest Stock News & Market Updates - StockTitan
Organovo reports positive Phase 2 results for liver drug FXR314 By Investing.com - Investing.com Australia
Organovo reports positive Phase 2 results for liver drug FXR314 - Investing.com India
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - The Manila Times
Organovo Holdings Inc Stock (ONVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):